NACLINDNSENACL Industries Limited· Fertilizers & AgrochemicalsHighNeutral
Announced Mon, 8 Dec, 2025 · 07:28 IST

NACL Industries Rights Issue record date fixed at Dec 12, 2025

NACLIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.4%Reaction day
₹174.00
prior close
₹174.89
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-2.4%-1.1% vs market
Pesticides & Agrochemicals peers, median of 27sector-2.4%-1.1% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.1 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.9
10m
-0.8
15m
-0.2
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.4-2.4-1.1-2.4-1.1
Next day
-0.2-0.4+0.3-1.2+1.1
2d
+4.8-1.1+5.9-2.4+7.2
3d
+10.1-0.6+10.7-2.2+12.3
4d
-0.2-0.4+0.2-2.5+2.3
5d
-2.8+0.1-2.9-1.9-1.0
1w
-7.2-1.4-5.8-3.2-4.1
15d
-8.0-1.0-7.1-2.1-6.0
1m
+3.2-0.8+4.0-4.6+7.8
2m
-20.7-0.9-19.7-5.3-15.3
3m
-31.8-11.3-20.5-16.6-15.1
UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NACL Industries has set December 12, 2025 as the record date for its Rights Issue. The company will issue 3.25 crore equity shares at Rs 76.70 each (including Rs 75.70 premium), raising up to about Rs 249.29 crores. Entitlement ratio is 5 Rights Shares for every 31 shares held. Issue opens Dec 22 and closes Dec 30, 2025.

Likely market impact

Eligible shareholders on the Dec 12 record date can apply at Rs 76.70 per share. Expect share dilution of about 16 percent post full subscription.